Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 226

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 8
Chunk 226
---
 Also, on June 25, 2025, we
sold an additional 2,315 shares of Series D Preferred Stock for gross cash proceeds of $1,852,000 in an additional closing of the Fourth
PIPE Financing. On July 18, 2025, the Company sold an additional 497 shares of Series D Preferred Stock for gross cash proceeds of $432,600
in an additional closing, and the Company received net proceeds of $320,801.

Each additional closing of
the PIPE Financings is at the option of the investors upon notice to the Company and subject to satisfaction of customary closing conditions.
Additional funds are necessary to maintain current operations and to continue R&D activities. However, there can be no assurance that
sufficient funding will be available to allow the Company to successfully continue its R&D activities and planned regulatory filings
with the FDA. If the Company is unable to obtain the necessary funds, significant reductions in spending and the delay or cancellation
of planned activities may be necessary. These actions would have a material adverse effect on the Company’s business, results of
operations, and prospects. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within
one year from the date these accompanying financial statements are issued. The accompanying financial statements do not include any adjustments
relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might
result from the outcome of this uncertainty.

Recent Developments

Reverse Stock Splits

At 12:01 a.m. Eastern time
on January 8, 2025, the Company effected the Reverse Stock Split pursuant to which each 100 shares of Common Stock outstanding immediately
prior thereto was converted into 1 share of Common Stock outstanding immediately thereafter, and at 12:01 a.m. Eastern time on June 13,
2025, the Company effected the Reverse Stock Split pursuant to which each 20 shares of Common Stock outstanding immediately prior thereto
was converted into 1 share of Common Stock outstanding immediately thereafter.

April 2025 PIPE Financing

As discussed above, on April
21, 2025, the Company entered into the Fourth Securities Purchase Agreement, pursuant to which the Company agreed to issue and sell up
to 10,000 shares of Series D Preferred Stock for an aggregate purchase price of up to $8 million in one or more closings which were completed
between April 22, 2025 through July 18, 2025.

35

In